Early PSA response among Black and non-Black patients with advanced prostate cancer treated with apalutamide
Future Oncology, our partner journal, has recently published a Short Communication article exploring prostate health following the administration of the medication apalutamide in a real-world urology practice setting. This was achieved by assessing PSA levels in patients with non-metastatic castration resistant prostate cancer (nmCRPC) or metastatic castration sensitive prostate cancer (mCSPC).
Abstract
Aim: To assess reduction in prostate-specific antigen (PSA) levels among Black and non-Black patients treated with apalutamide for nmCRPC or mCSPC.
Patients & Methods: Patients were identified from electronic medical data. PSA reduction (≥50%; ≥90%; or below 0.2 ng/mL) after apalutamide initiation was assessed.
Results: A total of 313 patients with nmCRPC and 260 patients with mCSPC were identified. The majority of patients treated with apalutamide achieved a 90% reduction in PSA regardless of indication or race. The proportion of patients achieving a PSA reduction at any level was similar among Black and non-Black patients and was consistent with apalutamide Phase III trials.
Conclusion: In routine clinical practice, apalutamide consistently produced rapid reduction in PSA levels in Black and non-Black men with nmCRPC or mCSPC.
Lay Abstract
This study looked at prostate health following treatment with the prostate cancer medication, apalutamide. Most patients had better prostate health after the medication, which was achieved after 2 months of treatment in most patients. Improvement in prostate health was similar in Black and non-Black patients.
